Chembio Diagnostics, a leading biotechnology company, has made headlines with its impressive portfolio of point-of-care (POC) diagnostic tests used to diagnose various diseases. The company offers a vast range of tests, including those for COVID-19, HIV, Syphilis, and Zika virus, as well as for lesser-known diseases such as Chagas, Ebola, and Leptospirosis. Chembio Diagnostics sells its products under multiple trademarks, including STAT-PAK, SURE CHECK, and NEXT GENERATION DPP, and distributes them through medical laboratories, hospitals, non-governmental organizations, and retail establishments across the globe. This pioneering company boasts collaboration agreements with influential organizations such as the Bill & Melinda Gates Foundation, The Paul G. Allen Family Foundation, and the Foundation for Innovative New Diagnostics, among others. Moreover, the company has partnered with various U.S. government agencies, including the Centers for Disease Control and Prevention, the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services, and the U.S. Department of Agriculture. Chembio Diagnostics was founded in 1985 and has its headquarters in Medford, New York. Its groundbreaking advances in the field of POC diagnostic tests have earned it a highly respected reputation throughout the industry.
Chembio Diagnostics's ticker is CEMI
The company's shares trade on the NASDAQ stock exchange
They are based in Medford, New York
There are 51-200 employees working at Chembio Diagnostics
It is chembio.com
Chembio Diagnostics is in the Healthcare sector
Chembio Diagnostics is in the Diagnostic Substances industry
The following five companies are Chembio Diagnostics's industry peers: